Opening New Frontiers In Cancer Treatment

Founded in St. Louis, Accuronix Therapeutics is a biotech company developing breakthrough treatments for the most difficult types of cancer. Accuronix was established based on technologies developed at Washington University by Dr. William Hawkins, Professor of Surgery, and his collaborator, Dr. Robert Mach, Professor of Radiology at University of Pennsylvania. With a particular focus in pancreatic cancer, the company’s mission is to develop novel oncology therapies founded on technology that selectively targets overexpressed receptors on cancer cells.

The Accuronix Approach

Accuronix Therapeutics is a leader in discovering and developing a new class of drugs that work by selectively targeting the σ-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. The Accuronix team has established an innovative platform and a lead drug candidate based on advances in characterizing the molecular-targeted drug conjugate (MTDC) approach to cancer therapy. The result is a chemotherapeutic with increased effectiveness and reduction in toxicity risk.

Accuronix Therapeutics is a Missouri Technology Corporation portfolio company.